This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

Arch Intern Med. 2000;160:149-150.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE BENEFITS of treating older patients with systolic hypertension have become well known since the completion of the Systolic Hypertension in the Elderly Program (SHEP),¹ a placebo-controlled trial that assessed the outcome of using diuretic-based antihypertensive therapy on stroke and related cardiovascular morbidities. Cardiovascular risk is increased substantially in older patients with hypertension when concomitant comorbid illlnesses such as diabetes mellitus² are present or if there is a history of vascular disease such as stroke or ischemic heart disease.³ Thus, much greater attention has been placed recently on the impact of blood pressure control in patients with hypertension and increased cardiovascular risk. For example, analyses of various outcomes from the diabetic subpopulation of the Systolic Hypertension in Europe (Syst-Eur) trial⁴ showed significant benefit for reduction of cardiovascular mortality and morbidity following treatment with the dihydropyridine calcium antagonist nitrendipine. In the Syst-Eur trial, active treatment in the patients with diabetes and . . . [Full Text of this Article]

RELATED ARTICLE

Chinese Trial on Isolated Systolic Hypertension in the Elderly
Ji-Guang Wang, Jan A. Staessen, Lansheng Gong, Lisheng Liu, and for the Systolic Hypertension in China Collaborative Group
Arch Intern Med. 2000;160(2):211-220.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cardiovascular Effects of the Cyclooxygenase Inhibitors
White
Hypertension 2007;49:408-418.
FULL TEXT  

Effects of a New Hormone Therapy, Drospirenone and 17-{beta}-Estradiol, in Postmenopausal Women With Hypertension
White et al.
Hypertension 2006;48:246-253.
ABSTRACT | FULL TEXT  

Antihypertensive Effects of Drospirenone With 17{beta}-Estradiol, a Novel Hormone Treatment in Postmenopausal Women With Stage 1 Hypertension
White et al.
Circulation 2005;112:1979-1984.
ABSTRACT | FULL TEXT  

Effects of the Selective Aldosterone Blocker Eplerenone Versus the Calcium Antagonist Amlodipine in Systolic Hypertension
White et al.
Hypertension 2003;41:1021-1026.
ABSTRACT | FULL TEXT